Actigraphy Sensors and Polysomnography Device Market | Latest Report, Market Analysis, Business Trends

Market Summary and Growth Forecast

The global Actigraphy Sensors and Polysomnography Device Market is estimated at $1,120 million in 2026 and is expected to reach $2,205 million by 2035, growing at a CAGR of 7.8%.

This estimate covers medical-grade actigraphy sensors, wrist-worn sleep assessment devices, in-lab polysomnography systems, portable PSG systems, sleep diagnostic recorders, associated sensors, signal acquisition modules, and clinical sleep analysis software sold with or alongside these systems. It excludes CPAP machines, APAP/BiPAP therapy devices, masks, oral appliances, consumer-only smartwatches, and sleep testing service revenue. The boundary is important. This is not the broader sleep apnea treatment market. It is the diagnostic and monitoring equipment layer that supports sleep medicine.

The Actigraphy Sensors and Polysomnography Device Market sits at the intersection of clinical diagnosis, remote monitoring, neurology, respiratory care, and digital health. Polysomnography remains the reference diagnostic test for many sleep disorders because it records multiple physiological channels such as EEG, EOG, EMG, ECG, airflow, respiratory effort, oxygen saturation, and body movement. AASM guidance continues to position polysomnography as the standard diagnostic test for obstructive sleep apnea when there is clinical concern, while also allowing technically adequate home sleep apnea testing in selected adult patients.

Actigraphy plays a different but complementary role. It is used to record sleep-wake patterns, circadian rhythms, rest-activity cycles, insomnia patterns, treatment response, and long-duration patient behavior outside the lab. AASM’s actigraphy guideline supports its use in adult and pediatric patients with suspected or diagnosed sleep disorders and circadian rhythm sleep-wake disorders.

The commercial relevance from 2026 to 2035 is clear. Sleep medicine is moving from single-night, lab-heavy testing toward a mixed model: hospital PSG for complex cases, portable PSG for distributed diagnosis, actigraphy for longitudinal sleep behavior, and AI-assisted scoring to reduce technician load. This shift does not remove the need for PSG. It changes where PSG is used and how often actigraphy and portable systems support triage, follow-up, and chronic monitoring.

The strongest demand signal comes from the large untreated pool of sleep-disordered breathing. A global prevalence study estimated nearly 1 billion adults aged 30–69 with obstructive sleep apnea. That creates structural demand for diagnosis, retesting, therapy follow-up, and risk stratification. The real bottleneck is not disease visibility alone. It is clinical capacity. Sleep labs face waiting lists, manual scoring workload, and reimbursement pressure. Devices that reduce setup time, allow home testing, or automate parts of analysis are therefore gaining budget priority.

Regulation is also shaping the market. In the United States, many actigraphy and sleep assessment devices move through the FDA 510(k) pathway. The ActiGraph LEAP activity monitor, for example, was cleared as a sleep assessment device under regulation 21 CFR 882.5050, while the Ambulatory Monitoring Sleep Watch received clearance in July 2025 for wrist-worn activity monitoring and sleep quantity/quality estimation using accelerometry. In Europe, the MDR environment raises the bar for clinical evidence, software documentation, post-market surveillance, and device traceability. This favors companies with quality systems and validated algorithms rather than low-cost hardware-only entrants.

From a manufacturing and supply standpoint, the market is not constrained by heavy industrial capacity. It is constrained by sensor accuracy, low-noise signal acquisition, wearable form factor, regulatory validation, software quality, electrode/sensor usability, and the ability to integrate data into clinical workflows. For PSG platforms, value sits in channel count, signal fidelity, amplifier quality, wireless reliability, patient comfort, and technician productivity. For actigraphy, value sits in battery life, wear compliance, algorithm transparency, data export, clinical validation, and longitudinal usability.

The Actigraphy Sensors and Polysomnography Device Market will grow because sleep testing is becoming more distributed. Hospitals are not the only buyers. Home sleep testing companies, neurology clinics, CROs, pharmaceutical sponsors, digital therapeutics firms, and academic research groups are also becoming relevant clients.

Core market indicators

Key consumers and clients include hospital sleep centers, independent sleep laboratories, pulmonology clinics, neurology departments, ENT practices, home sleep apnea testing providers, clinical trial sponsors, contract research organizations, academic sleep research units, pediatric sleep clinics, military fatigue-monitoring programs, and digital health platforms. Their buying logic is not identical. Hospitals want diagnostic confidence. Home testing providers want throughput and low failure rates. CROs want validated longitudinal data. Neurology researchers want signal consistency and exportable raw data.

Expert view: The next decade will not be a simple “lab versus home” story. The winning model will be layered. PSG will stay central for complex diagnosis. Actigraphy and portable systems will expand the front end and follow-up layer. AI will sit in between, turning raw sleep data into faster clinical interpretation.

Market Segmentation and Forecast Scope

The Actigraphy Sensors and Polysomnography Device Market is best segmented around device type, application, end user, and geography. A broad “sleep diagnostics” segmentation would be too loose because it would mix therapeutic devices, screening apps, and clinical-grade diagnostic systems. For this RD, the forecast scope is focused on revenue generated by equipment and associated clinical software.

Segmentation by product type

The product structure is led by PSG systems, followed by actigraphy sensors, portable PSG and home-based diagnostic systems, sleep analysis software, and recurring sensors/accessories.

In-lab PSG systems carry the largest revenue share in 2026 because of higher average selling prices and established clinical use. That said, portable PSG and home-compatible diagnostic platforms should outgrow the lab-only segment. This is where device makers can capture new volume without waiting for hospitals to build more sleep lab beds.

Actigraphy sensors should remain a smaller revenue pool than PSG systems, but their strategic value is rising. The reason is simple. They can capture multi-night patterns that a single PSG session may miss. They also fit clinical research, insomnia tracking, circadian rhythm disorder evaluation, and decentralized trials.

Segmentation by application

Application demand is anchored in obstructive sleep apnea. Yet the market is becoming broader. Insomnia, circadian rhythm disorders, hypersomnia, REM sleep behavior disorder, periodic limb movement disorder, pediatric sleep assessment, and drug trial endpoints are all relevant.

OSA diagnosis remains the largest application because it directly connects to therapy decisions, reimbursement pathways, and downstream treatment devices. CMS coverage supports Type I PSG for beneficiaries with clinical signs and symptoms of OSA when performed in an attended sleep lab, while home sleep testing also has a role in appropriate settings.

The more interesting growth sits in insomnia and circadian rhythm assessment. These cases often need multi-day or multi-week behavioral data rather than one night of lab testing. Actigraphy fills this gap. It gives clinicians an objective view of sleep timing, variability, and rest-activity patterns.

Expert view: OSA will pay the bills. Insomnia, circadian health, and neurology-linked monitoring will shape the premium end of the market. That’s where actigraphy moves from “nice to have” to clinically useful.

Segmentation by end user

The end-user base is shifting. Traditional sleep labs still dominate revenue, but home testing providers and research buyers are now more influential in product design.

Hospitals and sleep centers remain the largest end-user group in 2026 because PSG infrastructure is still concentrated there. They purchase full systems, software upgrades, electrodes, respiratory sensors, and replacement components. However, the fastest growth is likely to come from providers that can scale testing outside the lab.

Segmentation by region

The geographic scope includes North America, Europe, Asia Pacific, and LAMEA. Growth differs by reimbursement maturity, sleep lab density, device approval pathways, public awareness, and private diagnostic capacity.

North America leads because it has a larger installed base of sleep labs, stronger home sleep testing infrastructure, and better-developed reimbursement pathways. Asia Pacific is the strategic growth region. Japan and South Korea have advanced sleep medicine capabilities. China and India offer volume upside, although reimbursement and specialist availability remain uneven.

The segmentation of the Actigraphy Sensors and Polysomnography Device Market should therefore be read as a two-speed structure. PSG systems provide the clinical backbone. Actigraphy and portable systems provide the growth layer.

Market Trends and Innovation Landscape

Innovation in the Actigraphy Sensors and Polysomnography Device Market is moving toward portability, multi-night testing, AI-assisted scoring, and cleaner data capture. The old model relied heavily on attended sleep labs, manual scoring, and one-night assessment. That model still matters. But it is no longer enough for the volume of patients entering sleep pathways.

Trend 1: Portable PSG is becoming more clinically serious

Portable PSG is no longer viewed only as a compromise between full lab testing and basic home testing. Newer systems are trying to keep clinical-grade physiological signals while reducing patient burden. The direction is clear: fewer wires, easier setup, wireless transfer, better signal checks, and more flexible use across hospitals, clinics, and homes.

Nox Medical’s Nox A1 is positioned as a portable polysomnography system, while its broader platform messaging emphasizes home sleep testing services, connected workflows, actigraphy, respiratory measurements, and AI-enhanced scoring. Natus SleepWorks PSG is positioned around study setup, collection, review, analysis, reporting, multimodality, and cybersecurity. These product directions show where the market is going. Device companies are not selling recorders alone. They are selling a workflow.

Expert view: Portable PSG will not replace the full sleep lab. It will absorb cases that do not need the full cost and complexity of lab-based testing. That may increase total testing volume rather than simply shift existing revenue.

Trend 2: Actigraphy is being repositioned after legacy product exits

The actigraphy segment is going through a refresh cycle. One reason is the end of support for legacy products such as Philips Actiwatch, with support for several Actiwatch and Actiware products ending on December 29, 2023. That opened space for newer medical-grade actigraphy platforms from companies such as ActiGraph/Ametris, Ambulatory Monitoring, CamNtech, and neurocare/ActTrust.

The ActiGraph LEAP received FDA clearance as a sleep assessment device in 2023, and the Ambulatory Monitoring Sleep Watch received FDA clearance in 2025 for wrist-worn movement monitoring and sleep quantity/quality estimation. This matters because research buyers and clinical programs need validated continuity. They cannot simply replace medical-grade actigraphy with consumer wearables when regulatory-grade data quality is required.

Trend 3: AI-assisted scoring is moving from novelty to workflow infrastructure

Sleep labs face a practical problem. Scoring PSG and HSAT studies takes time. Skilled technologists are not unlimited. AI-assisted scoring helps reduce review burden, standardize interpretation, and speed report generation. This is especially relevant when testing volume expands through home and portable devices.

EnsoData has FDA-cleared AI-assisted sleep scoring and analysis tools, and its 2024 clearance expanded the ability to score data from FDA-cleared pulse oximeters. Earlier FDA documentation for EnsoSleep describes software intended to assist clinicians with sleep quality assessment and scoring of sleep-disordered breathing events from sleep study data.

The near-term impact is operational. Labs can process more studies with the same staff base. The longer-term impact is strategic. AI may become the layer that connects PSG, HSAT, actigraphy, oximetry, and longitudinal sleep datasets.

Expert view: AI will not remove clinician oversight in sleep diagnostics. The more realistic opportunity is assisted interpretation. That means faster scoring, fewer missed events, better workflow economics, and more consistent outputs across sites.

Trend 4: Home-compatible and single-use designs are gaining traction

Single-use and low-touch diagnostic devices are becoming more attractive for high-volume home testing. They reduce cleaning cycles, logistics friction, infection-control concerns, and device recovery issues. Compumedics Somfit received FDA clearance in 2023 as a home-based sleep monitoring device, and Somfit D received FDA clearance in 2025 as a single-use version that calculates and reports parameters including EEG channels, sleep stages, oxygen saturation, PAT signal, pulse rate, and snoring level.

This kind of product development is important for the Actigraphy Sensors and Polysomnography Device Market because it blurs the boundary between traditional PSG, home testing, and wearable diagnostics. The device that wins may not be the one with the most channels. It may be the one that produces enough clinically useful data with the fewest failed studies.

Trend 5: Partnerships are forming around data, not just hardware

Partnership activity is increasingly focused on software integration and data interpretation. In December 2024, BodiMetrics and EnsoData partnered to integrate AI-driven sleep scoring with a ring-based device for home sleep apnea testing and multi-night monitoring. React Health also announced a partnership with EnsoData to use AI-enabled sleep scoring and workflow tools within its sleep ecosystem.

This tells us where value is migrating. Hardware remains necessary. But the strategic layer is software, scoring, cloud workflow, and longitudinal patient data. Device makers that cannot connect into these systems may be pushed into lower-margin hardware supply.

Trend 6: Research is widening the use case beyond apnea

Recent research points to actigraphy and wearable sleep monitoring as tools for neurological screening, remote phenotyping, and broader sleep-wake analysis. Studies are exploring machine learning pipelines for REM sleep behavior disorder screening from actigraphy and device-agnostic sleep-wake determination using wrist accelerometry. These are not yet mass-market revenue pools. But they signal where premium demand could emerge, especially in neurology trials and long-duration patient monitoring.

Material science is not a major standalone driver in this market. The meaningful innovation is not in exotic materials. It is in sensor miniaturization, low-noise electronics, skin-contact comfort, adhesive design, battery efficiency, and signal-processing software. For PSG accessories, usability matters as much as raw performance. If sensors are uncomfortable or setup is too complex, study failure rates rise.

Innovation impact summary

The most important point is that innovation is not pushing the market in one direction. It is creating a tiered diagnostic system. Full PSG remains the clinical anchor. Portable systems increase reach. Actigraphy adds longitudinal context. AI makes the whole workflow more scalable.

Expert view: By 2035, the winners will likely be companies that combine validated signals, low-friction hardware, AI-supported interpretation, and clinical workflow integration. Standalone devices with weak software ecosystems will find it harder to defend pricing.

Competitive Intelligence and Benchmarking

Competition in the Actigraphy Sensors and Polysomnography Device Market is split across three layers: full PSG platforms, portable/home sleep diagnostic systems, and medical-grade actigraphy or digital sleep monitoring tools. The market does not behave like a pure hardware category. Buyers now judge suppliers on signal quality, software workflow, AI-readiness, clinical validation, service support, and ease of deployment.

Large hospital sleep labs still prefer reliable PSG systems with broad channel capability and stable software. Home sleep testing providers prefer lower-touch devices with fewer setup failures. Clinical research buyers want validated actigraphy, raw data access, and protocol flexibility.

Competitive benchmark by leading companies

Competitive interpretation

The PSG side is still led by suppliers with installed clinical systems, durable hardware, and trusted software. That favors Natus Medical, Nihon Kohden, Cadwell Industries, Compumedics, Nox Medical, and SOMNOmedics. The actigraphy side is more concentrated around medical-grade wearables and validated research platforms, where Ametris / ActiGraph has stronger recognition.

A useful way to benchmark the market is by revenue defensibility rather than simple product breadth.

Expert view: The most defensible competitors will not be the ones with the cheapest recorder. They will be the ones that reduce study failure, shorten scoring time, and produce data that clinicians trust. That is where margin protection sits.

In 2026, the top branded suppliers are estimated to account for roughly 45%–52% of the global covered revenue pool. The rest is spread across regional PSG suppliers, smaller HSAT device companies, actigraphy specialists, hospital accessory vendors, and sleep software firms. This fragmentation creates room for M&A. It also creates room for software partnerships, especially around AI-assisted scoring and remote monitoring.

Regional Landscape and Adoption Outlook

Regional demand in the Actigraphy Sensors and Polysomnography Device Market is shaped by three variables: diagnostic infrastructure, reimbursement, and sleep medicine awareness. Disease burden is high almost everywhere. But device revenue follows funded diagnosis, not disease prevalence alone.

Regional adoption snapshot

United States

The United States remains the commercial center of gravity. It has the largest installed base of sleep labs, the strongest home sleep apnea testing ecosystem, and the highest software monetization potential. Medicare coverage recognizes multiple sleep testing formats for OSA diagnosis, including attended Type I PSG and selected unattended portable testing categories, depending on clinical indication and device type.

The U.S. also has a practical capacity issue. PSG is clinically robust, but lab capacity and manual scoring can delay diagnosis. That is why portable PSG, HSAT platforms, AI scoring, and cloud-based study management are gaining attention. AASM guidance also supports home sleep apnea testing for uncomplicated adult patients when clinically appropriate, while PSG remains necessary when home tests are negative, inconclusive, or technically inadequate.

Expert view: The U.S. market is not shifting away from PSG. It is shifting toward smarter triage. Lab PSG handles complex patients. Home-compatible systems handle volume. Software links the two.

Europe

Europe is mature but more fragmented. Germany, the UK, France, Italy, Spain, and the Nordics lead adoption because of specialist availability, hospital infrastructure, and stronger sleep medicine pathways. Demand is supported by aging populations, cardiovascular comorbidity screening, and growth in outpatient diagnostics.

Regulation is a bigger strategic issue in Europe than in many other regions. The EU MDR framework increases documentation, clinical evidence, post-market surveillance, and software compliance requirements. The European Commission’s MDR guidance framework is central for companies trying to maintain or expand CE-marked medical device portfolios.

This makes Europe more difficult for low-evidence entrants. It also protects suppliers with validated PSG systems, documented software, quality systems, and post-market surveillance capabilities. In practical terms, Europe is good for serious manufacturers, but harder for opportunistic hardware vendors.

China

China is one of the most important growth markets through 2035. The country has a large OSA burden, with global prevalence research identifying China as the country with the highest number of affected individuals among reliable prevalence datasets.

Adoption is still more hospital-centric than in the U.S. Top-tier hospitals in major cities drive PSG demand. Private health systems and premium clinics are gradually adding sleep testing capacity. China’s growth will come from three areas: urban hospital expansion, broader awareness of sleep-disordered breathing, and localized lower-cost diagnostic systems. Local manufacturers may gain share in basic HSAT and monitoring devices, while imported brands remain stronger in premium PSG and validated clinical platforms.

India

India is underpenetrated but attractive. The country has a meaningful OSA burden, and published reviews have reported adult OSA prevalence ranges from 3.7% to 21% across Indian general population studies.

The challenge is not demand. It is diagnosis. Sleep labs are concentrated in metro cities, reimbursement is limited, and many patients pay out of pocket. That creates a market structure where lower-cost portable PSG, home testing, and clinic-based diagnostic workflows may scale faster than full sleep lab expansion.

India is likely to be one of the fastest-growing markets from 2026 to 2035, but from a small revenue base. Private hospital chains, pulmonology practices, ENT clinics, and digital health providers will be the main adoption channels. Government funding is not yet a major market driver for PSG hardware. Private healthcare spending matters more.

Japan

Japan has a mature sleep medicine base and strong hospital infrastructure. Demand is supported by aging, cardiovascular risk management, and established medical electronics acceptance. Recent Japanese research continues to show meaningful OSA relevance in clinical populations, including asthma and occupational cohorts.

Japan is not likely to be the fastest-growing country. It is more likely to remain a stable premium market. Buyers value reliability, regulatory compliance, clinical accuracy, and service support. Nihon Kohden benefits from domestic credibility here, while international suppliers compete in selected hospitals and research settings.

South Korea

South Korea has advanced tertiary hospitals, high digital health readiness, and a strong specialist base relative to population size. Published Korean studies show notable OSA risk in adults, including a 23.1% high-risk OSA estimate among Korean adults aged 40 years and above in one study, and other research has pointed to meaningful OSA burden in older adults.

The market is smaller than China and Japan but attractive for premium PSG, AI-enabled scoring, and hospital workflow software. Adoption will likely be led by university hospitals, sleep centers, and digital-forward clinics.

Middle East

The Middle East is relevant mainly through the Gulf markets: Saudi Arabia, UAE, Qatar, Kuwait, and Oman. These countries have higher private hospital spending, growing specialist care infrastructure, and elevated cardiometabolic disease burden. PSG and portable sleep diagnostics are most likely to be purchased by premium hospitals, respiratory clinics, neurology centers, and private diagnostic groups.

The constraint is specialist depth. A hospital can buy equipment faster than it can build a sleep medicine workforce. So the best-fit products are those that lower training burden, reduce failed studies, and offer remote or AI-assisted review.

Infrastructure, regulation, and funding comparison

Recent Developments + Opportunities & Restraints

Recent developments, last two years

Opportunities and business insights

1. Emerging markets are underdiagnosed, not under-demanded

Asia Pacific, India, China, and selected Middle Eastern markets offer strong growth because sleep disorder diagnosis is still underbuilt. The opportunity is not simply to sell premium PSG systems. It is to match the right device to the right care setting. Urban hospitals need full PSG. Private clinics need portable PSG and HSAT. Research institutions need actigraphy and validated data export.

Expert view: The best emerging-market strategy is tiered. Sell premium PSG to referral hospitals, portable systems to private clinics, and actigraphy to research and chronic monitoring programs.

2. AI scoring and automation can improve sleep lab economics

Manual scoring remains a bottleneck. AI-assisted tools can reduce technician burden, shorten turnaround time, and make sleep testing more scalable. This creates room for device makers to partner with scoring software companies or build their own analysis layers.

The commercial benefit is clear. A sleep lab that can process more studies without hiring proportionally more staff has a better return on equipment investment.

3. Remote monitoring creates a second revenue layer

Actigraphy and wearable-based monitoring can extend revenue beyond one-night diagnosis. This matters in insomnia, circadian rhythm disorders, pediatric follow-up, fatigue-risk monitoring, and clinical trials. A device sale can become a platform relationship if the supplier controls data capture, analytics, reporting, and support.

Key restraints

1. Reimbursement remains uneven

The U.S. has clearer coverage logic for PSG and selected home tests. Many other countries are less consistent. Where patients pay out of pocket, full PSG adoption grows slowly. This is a major restraint in India, parts of Southeast Asia, Latin America, and several Middle Eastern markets.

2. Clinical validation separates medical devices from consumer wearables

Consumer sleep trackers have increased awareness, but they do not automatically replace clinical PSG or medical-grade actigraphy. Suppliers must prove accuracy, maintain regulatory compliance, and support clinician review. This raises the entry barrier.

3. Setup failure and workflow friction still affect adoption

Home testing sounds simple, but failed studies remain a practical problem. Poor sensor placement, weak signal quality, upload issues, and patient non-compliance can raise costs. Products that reduce these errors will gain share faster than products that only compete on device price.